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Summary.-A recent publication from California in this journal has suggested that
both prolonged oral contraceptive use and abortion before first term pregnancy
increase the risk of breast cancer in young women. Data are presented on 1176
women aged 16-50 years with breast cancer, interviewed in London or in Oxford,
together with a like number of matched control subjects. The results are entirely
reassuring, being, in fact, more compatible with protective effects than the reverse.
Possible reasons for the differences between the 2 sets of data are discussed.
PIKE AND HIS COLLEAGUES (1981) have
recently reported the results of a case-
control study conducted in Los Angeles
County, U.S.A., involving 163 women
aged up to 32 years with breast cancer.
They found that oral-contraceptive (OC)
use for more than 48 months before first
term pregnancy was associated with an
almost 2*5-fold iicrease in risk. Shorter
durations of use and use after first-term
pregnancy did not appear to be important.
They also found that a first-trimester
abortion before first term pregnancy,
whether spontaneous or induced, was
associated with a 2*4-fold increase in
breast-cancer risk.
These provocative and worrying results
stimulated us to examine the relevant
data in our large case-control study of
breast cancer in young women which
first began in December 1968. We report
our findings here from a total of 1176
patients with cancer of the breast (210
ofwhom were aged 35 or less at diagnosis)
admitted to hospital up to the end of
September 1980.
METHODS AND SUBJECTS
Methods.-The methods used in our case-
control study have been described elsewhere
(Vessey et al., 1972, 1975, 1979). Briefly, up
to the end of 1971, married women aged
16-39 and being treated for newly diagnosed
breast cancer at University College, the
Royal Free, the Middlesex, Charing Cross
and Guy's hospitals, London, were inter-
viewed by a trained medical social worker or
a nurse about their medical, obstetric,
menstrual, contraceptive and social histories.
For each patient, 2 married controls were
selected from women inpatients in the same
hospital who had certain acute medical or
surgical conditions or had been admitted for
routine elective operations that were deemed
unlikely to be associated with the use or
lack ofuse ofany contraceptive. The controls
matched the women with breast cancer with
respect to age (within 5 years) and parity
(nil, 1-2, 3 or more term births) and were
interviewed inthe same way.
From January 1972 the procedure was
modified: the age range of the patients
with cancer was increased to 16-45; only
one control was selected for each case;
matching for age was arranged within 5-year
age groups (16-20, 21-25 and so on); and
a sixth hospital (Mount Vernon) agreed to
participate. Further extension of the study
followed in mid-1974: the age range was
increased to 16-50, and women admitted to
hospitals in the City of Oxford were also
included.
In the present paper, the overall results
are first presented as simple contingencyM. P. VESSEY, K. McPHERSON, D. YEATES AND R. DOLL
tables that take no account of the matched
design of the study. In subsequent analyses,
relative risks (RR) are estimated and allow-
ance is made for confounding variables, using
the "adapted" linear logistic procedure
described by Breslow et al. (1978). This
method preserves the matching and involves
the fitting of models for specified sets of
variables thought to influence the risk of the
disease. For simplicity, one of the pair of
controls matched with each ofthe 90 patients
with breast cancer interviewed before the end
of 1971 was deleted at random before
analysis (except that any control with gall-
bladder disease was preferentially deleted;
see below). Matching of cases and controls
is thus one-to-one throughout.
Subjects. From 1 December 1968 to 30
September 1980, 1262 women receiving
primary treatment for breast cancer were
interviewed together with 1262 matched
controls. Eighty-six of these controls had
gall-bladder disease. In view of the evidence
that gall-bladder disease may be an adverse
effect of OC use (Boston Collaborative Drug
Surveillance Programme, 1973), we omitted
these 86 controls and the corresponding
breast-cancer cases from the analysis, which
thus relates to 1176 case-control pairs.
Of the 1176 women with breast cancer,
210 were aged 16-35 and 127 were nulli-
parous.
RESULTS
Use of oral contraceptives before first term
pregnancy
Table I summarizes the data on use of
OC before the first term pregnancy re-
ported by the women in the 2 study
groups. The figures are given in 2 age and
2 parity groups as well as overall. There
is no suggestion of an association between
OC use and breast-cancer risk, even in
those with more than 48 months of expo-
sure before the first term pregnancy.
Data on the risks of breast cancer in
women using OC before the first term
pregnancy relative to those in women not
doing so, calculated according to the
method of Breslow et al. (1978), are
given in Table II. RRs are adjusted for
the confounding effects of social class
(4 groups), age at menarche (3 groups),
age at first term pregnancy (3 groups),
menopausal state (2 groups), smoking
habits (3 groups), history of breast
biopsy (2 groups) and family history of
breast cancer (2 groups). Once again, the
data are entirely negative (or, if anything,
suggestive of a modest protective effect
of OC use). Most of the RRs are substan-
tially lower than those that can be esti-
mated from the crude data presented in
Table I; this is mainly a consequence of
adjusting for the strongly confounding
effect of age at first term pregnancy, in
both age groups.
Pike et al. (1981) found evidence of a
significant positive interaction between
OC use before first pregnancy and a
history of benign breast disease. While
we failed to detect any such effect, our
data are too few for us to be confident
on this point.
Abortion beforefirst term pregnancy
The data reported by the study partici-
pants are shown in Table III. Only a
handful of women stated that they had
had a termination before their first term
pregnancy, so the figures for miscarriage
(spontaneous abortion) and termination
have been combined. It can be seen that
there is no indication of any association
between abortion before first term preg-
nancy and breast-cancer risk, either over-
all or in any of the subgroups defined by
age and parity (save, perhaps, among
nullipara aged up to 35 years, where the
numbers are too small for proper assess-
ment).
Table IV presents the RR calculated
as described in the previous section. The
data are, if anything, suggestive of a
modest protective effect of abortion be-
fore first term pregnancy on breast-
cancer risk.
DISCUSSION
The simplest explanation for the differ-
ence between our findings with respect to
the effects of OC use and those reported
by Pike et al. (1981) is the play of chance.
But this explanation is not very satis-
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TABLE I.-Total duration of use of oral contraceptives before first term pregnancy in
women with breast cancer and matched controls (percentages in parentheses)
Total
duration
OC use
Parity (months)
0 0
1-12
13-48
49 or more
Total
I or more 0
1-12
13-48
49 or more
Total
All parities 0
1-12
13-48
49 or more
Total
Age up to 35 yrs
Breast Ca. Control
8 (38-1) 5 (23 8)
2 (9 I) 2 (9.5)
5 (23 8) 6 (28 6)
6 (28 6) 8 (38-1)
21 21
157 (83 -1) 156 (82 5)
13 (6 9) 9 (4-8)
15 (7-9) 20 (10-6)
4 (2 - 1) 4 (2-1)
189 189
165 (78 6)
15 (7 - 1)
20(9 5)
10 (4-8)
210
161 (76-7)
11(5 2)
26 (12-4)
12 (5-7)
210
Age 36 yrs+
Breast Ca. Control
69 (65B1) 64 (60 4)
13 (12-3) 23 (21-7)
14 (13 -2) 9 (8 5)
10 (9 4) 10 (9 4)
106 106
838 (97 4) 840 (97 7)
15 (1-7) 16 (1-9)
3 (0*3) 2 (0.2)
4 (0.5) 2 (0 2)
860 860
907 (93 9) 904 (93 6)
28 (2 9) 39 (4-0)
17 (1-8) 11(1.1)
14(1-4) 12 (1-2)
966 966
All ages
Breast Ca. Control
77 (60 6) 69 (54 3)
15 (11-8) 25 (19-7)
19 (15-0) 15 (11-8)
16 (12-6) 18 (14-2)
127 127
995 (94 9) 996 (94 9)
28 (2 7) 25 (2-4)
18 (1-7) 22 (2-1)
8 (0 8) 6 (0 6)
1049 1049
1072 (91-2) 1065 (90 6)
43 (3 7) 50 (4 3)
37 (3 - 1) 37 (3 - 1)
24 (2 0) 24 (2 0)
1176 1176
TABLE II.-Risks of breast cancer in women using oral contraceptives before first term
pregnancy, relative to those in women not doing so*
Total duration
Parity OC use (months)
0
1-12
13-48
49 or more
1 or more
All parities
0
1-12
13-48
49 or more
0
1-12
13-48
49 or more
Age up to
35 yrs
1 00
0 77
0.59
0-67
1 00
0 74
0-56
0B55
Age 36+
1*00
0-48
1 .39
0 74
1 00
0.59
1 38
1 27
1 00
0-59
1-23
0 94
All ages
1 00
0 50
1 00
0-69
1 00
0 79
0 70
0 90
1 00
0- 70 (0-43-1 - 12)t
0-81 (0-47-1-39)
0-81 (0.43-1.53)
* Adjusted for effects of social class, age at menarch6, age at first term pregnancy,
menopausal state, smoking habits, history of breast biopsy and family history of breast
cancer.
t 95% confidence limits.
TABLE III.-Miscarriage or termination of pregnancy before first term pregnancy in
women with breast cancer and matched controls (percentages in parentheses)
Miscarriage/
Parity termination
0 No
Yes
Total
1 or more No
Yes
Total
All parities No
Yes
Total
Age up to 35 yrs
Breast Ca. Control
17 (81-0) 19 (90 5)
4(19-0) 2(9.5)
21 21
176 (93 -1) 170 (89 9)
13 (6 9) 19 (10-1)
189 189
193 (91.9) 189 (90 0)
17 (8 -1) 21 (10-0)
210 210
Age 36 yrs+
I' A
Breast Ca. Control
95 (89 6) 88 (83 0)
11 (10-4) 18 (17-0)
106 106
775 (90-1) 772 (89 8)
85 (9 9) 88 (10-2)
860 860
870 (90- 1) 860 (89 0)
96 (9 9) 106 (11-0)
966 966
All ages
Breast Ca. Control
112 (88.2) 107 (84 3)
15 (11-8) 20 (15-7)
127 127
951 (90-7) 942 (89 8)
98 (9 3) 107 (10-2)
1049 1049
1063 (90.4) 1049 (89 2)
113 (9 6) 127 (10-8)
1176 1176
0
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factory, as the probability of obtaining
such diverse results by chance alone
is small. Other explanations can be derived
from differences in the material studied
and, perhaps, in the methods of analysis.
These differences include at least 5 that
are potentially important.
First, Pike et al. (1981) initially identi-
fied 245 living patients as being eligible
for their study, but eventually succeeded
in including only 163 (67%) in the
analysis. Difficulties were also experienced
in assembling the 2 control series (made
up of "neighbourhood" controls and
"school-friend" controls). It seems pos-
sible that this incomplete response might
have affected their findings. Secondly,
relatively few of the British women had
used OC at all before their first term
pregnancy (23% of the control women
aged up to 35 years in the period 1968-80,
as against 48% in the Californian series
in the period 1972-78) and very few
had used them for more than 4 years
(5.7% against 9.6%). If the risk of breast
cancer increases sharply with duration
of use, the number of British women at
substantial risk must have been very
small and even proportionately small
within the group that had used OC for 4
years or more. Thirdly, our series of
young women included subjects up to
35 years of age (because of our matching
criteria), whereas the cut-off age in the
Californian series was 32. It is conceiv-
able (though unlikely) that OC use before
first term pregnancy affects the inci-
dence of breast cancer only in very young
women, and that its effect was diluted in
our series by extending the age limit to
35. Fourthly, whereas the Californian
series included women who were inter-
viewed several years after their cancer
was diagnosed, our series did not. Previous
studies have found that the survival rate
tends to be higher in women taking OC
at the time of diagnosis than in others
(Spencer et al., 1978; Vessey et al., 1979)
and, ifthis is generally true, it would tend
to produce a spurious association between
OC use and breast cancer in any series
that favoured long-term survivors. Pike
et al. (1981) "investigated this possible
bias by dividing cases into strata depend-
ing on the length of time from diagnosis
to interview, but found no evidence that
this influenced the OC finding". This,
however, does not wholly eliminate the
possibility, as the subjects were diagnosed
over a 6-year period (1972-78) during
which the use of OC in the population
might be expected to have increased.
Finally, the RRs in the 2 series were
standardized in different ways. Pike et al.
(1981) examined the effects of age at
menarche, family history of breast cancer
and whether or not women had had a full-
term pregnancy, and found that the RR
associated with OC use was "hardly
altered" by adjusting for them (whether
singly or in combination is unclear). They
did not, however, take account of age at
first term pregnancy, as there was no
clear trend in the risk with this variable.
The RR of breast cancer was, however,
materially less when first term pregnancy
occurred under 25 years of age (under
20 years 0-81, 20-24 years 0.67) and this
must have increased the period at risk
of OC use in the breast-cancer patients
compared with the controls. In our series,
in contrast, the RRs were standardized
(though crudely) for 7 factors relating to
the risk of breast cancer and OC use
(age at menarche, age at first term
pregnancy, history of breast biopsy,
family history of breast cancer, social
class, smoking habits, and-among women
aged 36 or more-menopausal status).
This standardization materially reduced
the estimates of RR associated with
long-term use of the drugs. It must be
stressed, however, that even without such
standardization, the RR for OC use for 4
years or more remains <1 for the young
group.
Summing up, we suspect that the
disparities between the results obtained
in Britain and California are due to the
combined effect ofchance, selective factors
associated with the availability of
subjects for interview, and (perhaps)
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TABLE IV.-Risks of breast cancer in women experiencing a miscarrtage or termination
ofpregnancy beforefirst term pregnancy relative to those in women not doing so*
Miscarriage/ Age up to Age 36 yrs
Parity termination 35 yrs or more All ages
O No 1*00 1*00
Yes - 0-62 0-73
1 or more No 1 00 1 00 1 00
Yes 0*62 0-84 0-84
All parities No 1 00 1 00 1.00
Yes 0 79 0-82 0-84 (0-63-1-12)t
* Adjusted for effects ofsocial class, age at menarch6, age at first term pregnancy, menopausal
state, smoking habits, history of breast biopsy and family history of breast cancer.
t 95% Confidence limits.
differences in the method of analysis.
We are encouraged to think that, when
more data are available and the effect of
random variation is reduced, the results
will not show any effect of OC use before
first term pregnancy on the incidence of
breast cancer in young women by: (i)
the consistency of the negative findings
in our series at ages up to 35 years and at
36 to 50 years and (ii) the lack of any
suggestion of an effect in the few cases so
far observed in the cohort being studied
in Oxford in conjunction with the Family
Planning Association (Vessey et al., 1981).
We note, however, that the Californian
series related to a population in which
OC had been used forlongperiodsbymore
women than in Britain, and for this reason
our negative results carry less weight
than would appear at first glance. More
data will, therefore, be needed relating to
the period before first term pregnancy for
both OC use and first-trimester abortion
(on which the 2 series also differed)
before any firm conclusion can be reached.
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